Double Bond Pharmaceutical (DBP) Q1 2025 earnings summary

Executive summary

• Clinical development preparations for lead candidate SI053 completed, with manufacturing process optimized and supply chain strengthened for upcoming Phase 1 study.

• Partnership agreement with Vivo Biopharma LLC extended, supporting strategic development and US market entry for SI053.

• Accounting policy change: development expenses now capitalized, restoring more than half of share capital.

Financial highlights

• Total group revenues for Q1 2025 reached SEK 1.4 million, up from SEK 0.4 million year-over-year.

• Operating loss improved to SEK -0.4 million from SEK -2.1 million year-over-year.

• Net loss for the period was SEK -1.1 million, compared to SEK -2.5 million in Q1 2024.

• Earnings per share were SEK -0.01, up from SEK -0.03 year-over-year.

Outlook and guidance

• All preparations in place to initiate clinical trials for SI053, with manufacturing and supply chain meeting EU cGMP standards.

• Ongoing negotiations with additional potential partners for SI053 outside the Vivo agreement.

• Monitoring US political and economic changes for potential impact on partnership and market access.